Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (278)	6/11/1998 11:14:00 AM
From: Anthony Wong	Respond to of 1722

DuPont Merck Looks For Speedy Review After Sending HIV Drug To FDA Dow Jones News Service June 11, 1998 10:43 AM WASHINGTON -(Dow Jones)- DuPont Merck Pharmaceutical Co. said Thursday it sent its new drug application for Sustiva, an HIV drug that is taken once a day, to the Food and Drug Administration. The FDA, which designated Sustiva a fast-track drug, plans to make a decision on the product within six months. DuPont & Co. (DD) announced last month that it will buy Merck & Co.'s (MRK) 50% interest in their DuPont Merck venture for $2.6 billion. The deal, expected to close July 1, will make Sustiva the first HIV drug of the new DuPont Pharmaceuticals Co. if it is ultimately approved. The drug belongs to a class of drugs known as nonnucleoside reverse transcriptase inhibitors. As a once-daily HIV treatment in combination with other antiretrovirals, it would have advantages over other medicines. Most AIDS drugs must be taken several times a day, some with food and some without food, making dosing regimens complicated. Sustiva was initially developed and then set aside in the early 1990s by Merck, and then was resurrected by DuPont Merck. Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.

To: Anthony Wong who wrote (278)	6/11/1998 11:17:00 AM
From: Anthony Wong	Respond to of 1722

Merck To Build $300 Million Chemical Plant In Singapore June 11, 1998 9:41 AM SINGAPORE -(Dow Jones)- U.S. pharmaceuticals giant Merck & Co. Thursday said it would build a $300 million chemical plant in Singapore for its health products. The plant is expected to be operational in 2001, the company said. No capacity figures were given. Merck (MRK) said the project is necessary because demand for its products has "grown significantly in recent years." Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.